Download presentation
Presentation is loading. Please wait.
Published byΚαλλικράτης Δελή Modified over 5 years ago
1
Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice Abdalla Awidi, Salah Abbasi, Kamal Alrabi, Khalid A. Kheirallah Clinical Lymphoma, Myeloma and Leukemia Volume 17, Issue 12, Pages e55-e61 (December 2017) DOI: /j.clml Copyright © 2017 The Authors Terms and Conditions
2
Figure 1 Flowchart of Patients
Clinical Lymphoma, Myeloma and Leukemia , e55-e61DOI: ( /j.clml ) Copyright © 2017 The Authors Terms and Conditions
3
Figure 2 Response in the First-line Patients at Month 12. Ten (30% of 33) Patients Had No Efficacy Data at Month 12, and Therefore Were Excluded From the Evaluable Patients and Included in the ITT Population Abbreviations: CCyR = complete cytogenetic response; ITT = intention-to-treat; MMR = major molecular response; PCyR = partial cytogenic response. Clinical Lymphoma, Myeloma and Leukemia , e55-e61DOI: ( /j.clml ) Copyright © 2017 The Authors Terms and Conditions
4
Figure 3 Response in Switched Patients at Month 12. Three (5% of 58) Patients Had No Efficacy Data at Month 12, and Therefore Were Excluded From the Evaluable Patients and Included in the ITT Population Abbreviations: CCyR = complete cytogenetic response; ITT = intention-to-treat; MMR = major molecular response; PCyR = partial cytogenic response. Clinical Lymphoma, Myeloma and Leukemia , e55-e61DOI: ( /j.clml ) Copyright © 2017 The Authors Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.